Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Anaemia
Interventions: Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 161
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more

Conditions: Iron Deficiency, Anaemia
Interventions: Ferric carboxymaltose; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: Up to 1 Year
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Iowa City, Iowa • New Hyde Park, New York • Columbus, Ohio + 1 more

Conditions: Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Interventions: Vamifeport, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • San Diego, California • Jacksonville, Florida + 16 more

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate, PA21-1 (1.25 g tablet containing 250 mg iron); Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,059 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Kidney Diseases
Interventions: Ferric Citrate, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Years to 18 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 14 more

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anemia
Interventions: Ferric Carboxymaltose, Iron Dextran; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Iron-deficiency, Pregnancy, High Risk, Stress, Psychological
Interventions: Probiotic LP299v 10x10 colony forming units in capsule form, Placebo in capsule form; Dietary Supplement · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anemia, Iron Deficiency Anemia
Interventions: Treatment with oral sucrosomial iron, Treatment with intravenous iron; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Myelodysplastic Syndromes
Interventions: Deferasirox, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 11
States / cities: Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide; Drug · Radiation
Lead sponsor: Bryan Allen; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Iron Overload
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 78 Months to 25 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation; Biological · Other · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 30 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: AIDS Dementia Complex
Interventions: Ferumoxytol; Drug
Lead sponsor: Beau Nakamoto; Other
Eligibility: 40 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Iron Overload, Beta-Thalassemia
Interventions: SP-420; Drug
Lead sponsor: Sideris Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania

Conditions: Hemochromatosis, Iron Overload
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide, Pegfilgrastim, Filgrastim; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 74 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Rockford, Illinois • Madison, Wisconsin • Milwaukee, Wisconsin + 2 more

Conditions: Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions: FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate); Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Hereditary Hemochromatosis
Interventions: LJPC-401, Placebo; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
Interventions: 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, High Field Strength Magnetic Resonance Imaging, Susceptibility Weighted Imaging; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Contrast-Induced Acute Kidney Injury
Interventions: CRMD-001-Deferiprone, Placebo; Drug
Lead sponsor: CorMedix Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more

Conditions: SAH, Dementia
Interventions: Deferiprone pill, placebo, Montreal Cognitive Assessment; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Iowa City, Iowa • Durham, North Carolina

Conditions: Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
Interventions: Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Search by objective public record fields.

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients

Ferric Citrate and Chronic Kidney Disease in Children

Iron Mediated Vascular Disease in Sickle Cell Anemia Patients

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia

A Randomized Placebo Controlled Pilot Study of Probiotic Supplementation in At-risk Pregnant Women

Sucrosomial Vs Intravenous Iron for Preoperative Anemia

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Iron Overload in Pediatric Oncology Patients

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

Iron Overload in African Americans

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

Ferritin and Iron Burden in SAH sIRB

Estrogen and Microvascular Function